Age-Related Cognitive Decline

🔍 Four Things You Likely Didn’t Know About Age-Related Cognitive Decline

1. Many people who think they have early dementia actually have something completely treatable. Depression can mimic cognitive decline so convincingly that it has its own clinical name: pseudodementia. Sleep disorders, medication side effects, thyroid dysfunction, chronic low-grade inflammation or persistent infections (e.g., Lyme, COVID), and B12 deficiency can do the same — and the difference is that these are often reversible.

2. Some people’s brains are laden with Alzheimer’s pathology — yet they never showed a single symptom. Autopsies of cognitively normal older adults sometimes reveal substantial Alzheimer’s damage, demonstrating that the brain can compensate for remarkable amounts of pathology. This buffer — called cognitive reserve — is built through education, intellectual engagement, and social connection, and it can be strengthened throughout life.

3. The most important time to protect your brain from dementia is decades before any symptoms appear — and roughly 40% of dementia cases may be attributable to modifiable risk factors. The 2024 Lancet Commission identified 14 such factors (Livingston et al., 2024), many of which are treatable and most of which are rarely evaluated in routine medical care. A thorough cognitive evaluation reviews each of these methodically, determines which are relevant for a given individual, and builds a targeted prevention or intervention strategy — because the window for meaningful action closes earlier than most people realize.

4. How you think about aging may matter as much as how your brain ages. A Yale study tracked 660 older adults for over two decades: those with positive self-perceptions of aging lived an average of 7.5 years longer — an effect larger than the benefit of not smoking, exercising, or maintaining a healthy weight (Levy et al., 2002). It suggests that identifying what gives your life meaning, recognizing how many of those sources deepen with experience rather than diminish, and addressing the distorted thinking patterns that frame aging as pure loss can itself be a form of neuroprotection.

---

📋 Overview

As the brain ages, certain cognitive functions naturally change. Processing speed begins declining as early as the mid-twenties (Salthouse, 2009), the ability to hold multiple items in working memory may diminish, and the ease of recalling names, words, and specific details may decrease. These changes are a normal part of aging and do not, in themselves, indicate disease. The vast majority of healthy older adults maintain the capacity for independent functioning, new learning, and meaningful intellectual engagement throughout their lives.

However, cognitive aging is far from a story of uniform decline. Vocabulary, accumulated knowledge, emotional regulation, and the integrative judgment that people recognize as wisdom tend to remain stable or improve with age — in some cases well into the seventh and eighth decades. The aging brain is not simply deteriorating; it is reorganizing and in many cases, enriching.

When cognitive changes exceed what is expected for a person’s age, the condition may meet criteria for mild cognitive impairment (MCI) — an intermediate zone between normal aging and dementia. About 10–15% of people with MCI progress to dementia each year, but a substantial proportion remain stable or even revert to normal cognition — particularly when modifiable contributing factors are addressed.

Subjective cognitive decline (SCD) — noticing worsening cognition despite normal test results — affects up to 25% of older adults. While SCD can sometimes represent the earliest awareness of incipient neurodegeneration, it is often driven by other causes including mood and medication effects. The clinical challenge is to take the complaint seriously without over-worrying — anxiety about cognitive decline can itself worsen perceived memory performance, creating a self-reinforcing cycle. A proactive evaluation is the most effective way to break the cycle. In many cases, detailed neuropsychological assessment is the most direct path to separating perception from reality.

---

🧬 Evolutionary Perspective

The cognitive changes of normal aging are not simply deterioration — they reflect shifts that may have carried adaptive value. In ancestral communities — and in many cultures that still recognize their importance today — older members were valued not for the speed with which they could hunt or build a house but for accumulated wisdom, social judgment, and the ability to integrate decades of experience.

Research in cognitive aging supports this: while fluid intelligence (speed, novel problem-solving) declines with age, crystallized intelligence (vocabulary, general knowledge, experiential wisdom) remains stable or continues to improve well into the seventh and eighth decades (Salthouse, 2012). Emotional regulation also tends to improve with age — older adults are often better at managing emotional responses, resolving interpersonal conflicts, and prioritizing meaningful experiences over novel ones.

This does not minimize the genuine distress of cognitive slowing or the real risk that certain changes may signal pathology. But it provides important context: the aging brain is not simply a declining brain. It is a brain that processes differently — and in some domains, arguably more effectively.

---

🔀 Key Distinctions

Distinguishing between normal aging, mild cognitive impairment, and early dementia is one of the most consequential diagnostic challenges in medicine. The following framework is clinically useful:

• Normal age-related cognitive changes — occasional word-finding or object-finding difficulty, slower processing speed, needing more time to learn new information, or modest difficulty multitasking. Critically, day-to-day functioning remains intact, and the person can compensate with strategies and effort.
• Subjective cognitive decline (SCD) — the patient reports cognitive worsening, but standardized testing shows performance within normal limits for age. However, it may reflect early neurodegeneration, depression, anxiety, sleep disorder, medication effects, or heightened self-awareness. Warrants thorough evaluation and longitudinal monitoring.
• Mild cognitive impairment (MCI) — objective cognitive decline on testing that exceeds age expectations, but preservation of functional independence. MCI is further classified as amnestic (primarily affecting memory, with a higher risk of progression to Alzheimer’s) or non-amnestic (affecting other domains such as language, attention, or executive function, with a more heterogeneous prognostic trajectory).
• Dementia — cognitive decline severe enough to interfere with independent daily functioning. This is a clinical threshold, not a specific disease — dementia is a syndrome with many possible causes. Fortunately, we now have several excellent diagnostic tools — including blood-based biomarkers and advanced neuroimaging — that can assess with high precision whether a neurodegenerative process such as Alzheimer’s disease is present, complementing and strengthening the clinical assessment.

Understanding where a person falls on this spectrum — and, crucially, whether a treatable condition is driving or contributing to the cognitive changes — is the central purpose of a comprehensive evaluation.

---

🩺 Diagnosis

A thorough diagnostic evaluation for cognitive concerns involves multiple components:

• Detailed clinical history — the nature, timeline, and pattern of cognitive complaints; the patient’s own observations and the perspective of a family member or close friend; impact on daily functioning; medication and substance use history; sleep patterns; mood and anxiety symptoms; and medical comorbidities.
• Cognitive screening and neuropsychological testing — brief screening instruments provide an initial assessment, but formal neuropsychological testing offers a far more detailed and nuanced picture. Testing can identify the specific cognitive domains affected, quantify the degree of impairment, and generate a cognitive “fingerprint” that helps distinguish between different etiologies.
• Psychiatric assessment — this is critical and often underemphasized. Depression, generalized anxiety, chronic insomnia, and grief can all produce cognitive symptoms indistinguishable from early MCI on brief screening. A thorough psychiatric evaluation can identify these conditions and guide treatment that may resolve or substantially improve the cognitive complaints.
• Medical workup — laboratory evaluation including baseline measures and at times more complex ones like inflammatory markers, infection panels, heavy metals, key nutritional deficiencies that are sometimes ignored, among other tests as clinically indicated. Screening for sleep apnea — a remarkably common and frequently undiagnosed cause of cognitive impairment — may be appropriate.
• Medication review — anticholinergic medications, benzodiazepines, opioids, certain antihistamines, and numerous other commonly prescribed drugs can impair cognition, particularly in older adults. A careful medication review can identify “pharmacological fog” that is entirely iatrogenic (i.e., doctor-caused) and reversible.
• Neuroimaging — structural MRI may be indicated to evaluate for vascular disease, hippocampal atrophy, or other structural pathology. In select cases, amyloid or tau PET imaging or cerebrospinal fluid biomarkers may be considered, though these are not routine for most patients presenting with cognitive complaints.

The evaluation should answer two fundamental questions: Is something treatable contributing to these cognitive changes? And what is the risk of progression?

---

💊 Treatment Approach

The treatment of age-related cognitive decline is determined by what the evaluation reveals — and the range of possibilities is far wider than most people expect.

Psychotherapy and Behavioral Approaches

When depression or anxiety is contributing to cognitive symptoms — as it frequently is — psychotherapy can be remarkably effective. Metacognitive therapy and Acceptance and Commitment Therapy (ACT) are particularly well suited for this population: metacognitive strategies help patients observe and manage their cognitive processes rather than be overwhelmed by them, while building psychological flexibility in the face of day-to-day uncertainty. Cognitive rehabilitation — structured training in compensatory strategies for memory, attention, and organization — can improve functional performance and reduce the frustration that accompanies cognitive changes. CBT for late-onset depression remains a well-supported option for patients.

For patients and families coping with an MCI diagnosis, supportive psychotherapy provides a space to process the fear of losing oneself, the grief of anticipated decline, and the practical questions about an uncertain future.

Medication and Neuromodulation

When a treatable medical or psychiatric condition is driving cognitive symptoms, targeted pharmacological treatment is the most impactful intervention available. Antidepressant therapy for depression-related cognitive impairment can produce dramatic improvement, sometimes restoring cognitive performance to premorbid levels. Treatment of insomnia, anxiety, and ADHD (which can present or worsen in later life) can similarly yield meaningful cognitive benefits.

For patients with MCI who are at elevated risk for progression to dementia, the evidence base for pharmacological intervention is evolving. Cholinesterase inhibitors, while approved for dementia, can be used off-label in MCI, and may be particularly helpful for some patients. The decision to use these agents in MCI is individualized.

Neuromodulation — including transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), photobiomodulation typically using between 800-1100 nm light, and other emerging neuromodulation techniques — is an active area of investigation for cognitive enhancement in both normal aging and MCI. While these approaches are not yet standard of care for cognitive decline, preliminary evidence has shown rather promising results in many cases, and they are worth considering as part of a thorough and comprehensive strategy.

Equally important is the process of strategic deprescribing — systematically reviewing and, where possible, reducing or eliminating medications, supplements, and other interventions that may be contributing to cognitive impairment. This is often one of the highest-yield interventions in geriatric psychiatry.

Integrative and Lifestyle Approaches

The evidence supporting lifestyle interventions for cognitive health is among the strongest in all of preventive medicine. Structured aerobic exercise, cardiovascular risk factor management, cognitive engagement, social connection, sleep optimization, and dietary planning are all associated with reduced risk of cognitive decline and dementia in observational and, increasingly, in interventional studies. The FINGER trial demonstrated that a multimodal lifestyle intervention could meaningfully improve cognitive outcomes in at-risk older adults (Ngandu et al., 2015). Specific interventions targeting neuroinflammation, metabolic health, hormonal factors, and micronutrient status need to be tailored to the individual’s biology and risk profile.

There is no algorithm that replaces careful clinical judgment informed by a thorough understanding of this condition.

---

🌱 Outlook

The outlook for age-related cognitive decline depends entirely on its cause.

For the substantial number of patients whose cognitive complaints are driven by non-structural causes - like depression, insomnia, iatrogenic effects, among others - the prognosis is excellent and improvement is rapid. Treatment of the underlying cause can produce dramatic cognitive improvement.

For patients with MCI, the outlook is more nuanced but not as dire as many fear. The annual conversion rate from MCI to dementia is approximately 10–15%, but a significant proportion of MCI patients remain stable or improve — particularly when modifiable risk factors are addressed.

For those who are experiencing normal age-related cognitive changes and are frightened that they may be developing dementia, the most valuable intervention may simply be an accurate evaluation that provides clarity, context, and evidence-based reassurance. Notably, this deeper understanding complemented by a shift in perspective may itself be protective: longitudinal research shows that individuals who approach aging with a positive, engaged mindset demonstrate measurably better cognitive and physical outcomes over decades (Levy et al., 2002).

---

🏥 How to Get Better

At our psychiatry practice, we have extensive experience in evaluating and treating age-related cognitive decline — helping distinguish normal aging from early pathological processes — and bring a thoughtful, evidence-based approach to managing it with medications – when needed – and psychotherapy and — when appropriate and desired by the patient — with other modalities including supplements, neuromodulation, stress management, movement planning, and holistic practices among others.

Ready to get started? Schedule an intake appointment — a thorough evaluation where we clarify your diagnosis, map out your treatment plan, and get everything moving: medication orders, therapy, supplements, and nutrition. Your care begins the same day, not weeks later.

Schedule Your Intake

We offer statewide telehealth services in California and Florida, with in-person appointments available in Los Angeles and Miami. We also regularly assist international patients due to our fluency in Portuguese, Spanish, and Farsi.

---

📚 References

1. Stern, Y. (2012). Cognitive reserve in ageing and Alzheimer’s disease. The Lancet Neurology, 11(11), 1006–1012.
2. Petersen, R. C., Lopez, O., Armstrong, M. J., et al. (2018). Practice guideline update summary: mild cognitive impairment. Neurology, 90(3), 126–135.
3. Livingston, G., Huntley, J., Liu, K. Y., et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, 404(10452), 572–628.
4. Ngandu, T., Lehtisalo, J., Solomon, A., et al. (2015). A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The Lancet, 385(9984), 2255–2263.
5. Jessen, F., Amariglio, R. E., Buckley, R. F., et al. (2020). The characterisation of subjective cognitive decline. The Lancet Neurology, 19(3), 271–278.
6. Kang, H., Zhao, F., You, L., Giorgetta, C., Venkatesh, D., Sarkhel, S., & Bhowmick, T. (2014). Pseudo-dementia: a neuropsychological review. Annals of Indian Academy of Neurology, 17(2), 147–154.
7. Salthouse, T. A. (2012). Consequences of age-related cognitive declines. Annual Review of Psychology, 63, 201–226.
8. Craik, F. I. M. (2002). Levels of processing: past, present, and future? Memory, 10(5–6), 305–318.
9. Langa, K. M., & Levine, D. A. (2014). The diagnosis and management of mild cognitive impairment: a clinical review. JAMA, 312(23), 2551–2561.
10. Smart, C. M., Karr, J. E., Areshenkoff, C. N., et al. (2017). Non-pharmacologic interventions for older adults with subjective cognitive decline: systematic review, meta-analysis, and preliminary recommendations. Neuropsychology Review, 27(3), 245–257.
11. Levy, B. R., Slade, M. D., Kunkel, S. R., & Kasl, S. V. (2002). Longevity increased by positive self-perceptions of aging. Journal of Personality and Social Psychology, 83(2), 261–270.
12. Salthouse, T. A. (2009). When does age-related cognitive decline begin? Neurobiology of Aging, 30(4), 507–514.